SPOTLIGHT: Amgen, Roche square off

Amgen and Roche head into court today to continue their fight over anemia drugs. Roche wants to market Mircera, its treatment for the malady, but Amgen claims the drug violates Amgen patents. Last week, Roche thumbed its nose at Amgen, saying it will sell Mircera as soon as the FDA gives its OK--whether Amgen likes it or not. We'll see whether the court has other ideas. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.